Flag of the European Union EU Clinical Trials Register Help

Clinical trials for cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    10,211 result(s) found for: cancer. Displaying page 222 of 511.
    «« First « Previous 218  219  220  221  222  223  224  225  226  Next» Last»»
    EudraCT Number: 2007-005666-12 Sponsor Protocol Number: IMA910-101 Start Date*: 2008-04-15
    Sponsor Name:immatics biotechnologies GmbH
    Full Title: An open label, multicenter Phase 1-2 study to investigate the effectiveness, safety and immunogenicity of a monotherapy with intradermal IMA910 plus GM-CSF following pre-treatment with low-dose cyc...
    Medical condition: Adult HLA-A*02-positive patients who have been diagnosed with unresectable, locally advanced and/or metastatic colorectal cancer before first-line chemotherapy. Patients must have completed a 12 we...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BE (Completed) GB (Completed) LV (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004865-28 Sponsor Protocol Number: CLAG525B2101 Start Date*: 2018-12-05
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or s...
    Medical condition: triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005175-78 Sponsor Protocol Number: SAMSON-II Start Date*: 2019-10-10
    Sponsor Name:Prestige BioPharma Limited
    Full Title: A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metas...
    Medical condition: Non-squamous Non-small Cell Lung Cancer (nsNSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) GR (Completed) PL (Completed) BG (Completed) LV (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004749-32 Sponsor Protocol Number: D4200C00032 Start Date*: 2006-04-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Double-Blinded, Multi-Centre Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination with ZD6474 (ZACTIMA™) versus Docetaxel (TAXOTERE™) in combination with Pl...
    Medical condition: Non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) ES (Completed) AT (Completed) BE (Completed) GR (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002814-38 Sponsor Protocol Number: SP005 Start Date*: 2013-09-27
    Sponsor Name:SOTIO a.s.
    Full Title: A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer elig...
    Medical condition: metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) BE (Completed) CZ (Completed) IT (Completed) NL (Completed) ES (Completed) HU (Completed) PT (Completed) BG (Completed) SK (Completed) PL (Completed) HR (Completed) AT (Completed) LV (Completed) LT (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001921-34 Sponsor Protocol Number: C31001 Start Date*: 2015-04-30
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Bre...
    Medical condition: ER+/HER2- Advanced or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003736-77 Sponsor Protocol Number: IRFMN-OVA-7814 Start Date*: 2020-06-10
    Sponsor Name:Istituto di Ricerche Farmacologiche Mario Negri IRCCS
    Full Title: A multicenter, open-label phase II trial of a new customized dosing (Rational Adjustment of Dose to reduce Adverse Reactions “RADAR” dosing) of niraparib as maintenance therapy in platinum sensitiv...
    Medical condition: Ovarian, fallopian tube or primary peritoneal recurrent cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10038604 - Reproductive system and breast disorders 10038604 Reproductive system and breast disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003185-25 Sponsor Protocol Number: GO29058 Start Date*: 2015-03-03
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE AND HER2 NEGATI...
    Medical condition: WOMEN WITH ER-POSITIVE AND HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAS DIDEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) PT (Completed) ES (Completed) CZ (Completed) DE (Completed) AT (Completed) NL (Completed) PL (Completed) BG (Completed) FR (Completed) SE (Completed) GR (Completed) RO (Ongoing) FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-002766-20 Sponsor Protocol Number: CAUY922A2101 Start Date*: 2009-02-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in...
    Medical condition: Dose-expansion study to assess safety, tolerability & efficacy: -One arm (MTD expansion) will enroll advanced cancer patients (other than breast carcinoma). -Two arms (phase II) to assess response ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001325-24 Sponsor Protocol Number: SOV03 Start Date*: 2013-08-30
    Sponsor Name:SOTIO a.s.
    Full Title: A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to standard chemotherapy in women with relapsed platinum resistant epith...
    Medical condition: epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002918-41 Sponsor Protocol Number: IJB-EBC-Decrescendo-2020 Start Date*: 2021-08-25
    Sponsor Name:Institut Jules Bordet
    Full Title: De-Escalation of neoadjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chem...
    Medical condition: HER2-positive, estrogen receptor (ER)-negative/progesterone receptor (PR)-negative, node-negative early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) IT (Prematurely Ended) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002868-28 Sponsor Protocol Number: D6995C00006 Start Date*: 2005-12-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Open-Label, Parallel-Group, Multi-centre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as First Line H...
    Medical condition: Hormone Receptor Positive Advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001642-18 Sponsor Protocol Number: D8230C00002 Start Date*: 2021-05-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies
    Medical condition: Haematological Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001008-14 Sponsor Protocol Number: AT148006 Start Date*: 2021-10-25
    Sponsor Name: ALX Oncology Inc.
    Full Title: A Phase 2/3 Study of ALX148 in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma
    Medical condition: Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10017770 Gastric carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000743-31 Sponsor Protocol Number: 73841937NSC3003 Start Date*: 2020-09-23
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR Mutated Locally Advanced or Metastat...
    Medical condition: EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PT (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004698-17 Sponsor Protocol Number: MedOPP067 Start Date*: 2015-05-07
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with HER2 negative, ER+ metastatic ...
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) IT (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-003092-22 Sponsor Protocol Number: CO39385 Start Date*: 2017-05-02
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE...
    Medical condition: Metastatic Castration-Resistant Prostrate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) CZ (Completed) DK (Completed) DE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Completed) BE (Completed) GR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001285-10 Sponsor Protocol Number: CA209-171 Start Date*: 2015-05-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at...
    Medical condition: Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) DE (Completed) FI (Completed) DK (Completed) PT (Completed) ES (Ongoing) AT (Completed) GB (GB - no longer in EU/EEA) IE (Completed) GR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-003083-21 Sponsor Protocol Number: GO29431 Start Date*: 2015-08-20
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH A PLATINUM AGENT (CISPLATIN OR CARBOPLATIN) IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR ...
    Medical condition: Stage IV Non-Squamous or Squamous Non−Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Prematurely Ended) ES (Ongoing) GR (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004265-39 Sponsor Protocol Number: VS-6766-202 Start Date*: 2021-08-27
    Sponsor Name:Verastem, Inc.
    Full Title: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell ...
    Medical condition: Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 218  219  220  221  222  223  224  225  226  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 08:02:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA